iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Up 112.4% in February

iBio, Inc. (NYSEAMERICAN:IBIO) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 454,200 shares, a growth of 112.4% from the January 31st total of 213,800 shares. Based on an average daily trading volume, of 239,400 shares, the days-to-cover ratio is presently 1.9 days. Currently, 4.9% of the company’s stock are short sold.

iBio Stock Performance

NYSEAMERICAN:IBIO traded up $0.78 during trading hours on Friday, reaching $5.83. 1,352,886 shares of the company traded hands, compared to its average volume of 492,873. iBio has a 1 year low of $1.05 and a 1 year high of $5.83. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04.

About iBio

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.